吉非替尼
神经母细胞瘤
MTT法
癌症研究
酪氨酸激酶
酪氨酸激酶抑制剂
细胞毒性T细胞
细胞生长
细胞培养
医学
药理学
化学
表皮生长因子受体
内科学
体外
癌症
生物
生物化学
受体
遗传学
作者
Kyriaki Hatziagapiou,Maria Braoudaki,Michael Karpusas,Fotini Tzortzatou-Stathopoulou
出处
期刊:Clinical Laboratory
[Clinical Laboratory Publications]
日期:2011-01-01
卷期号:57 (9-10): 781-4
被引量:4
摘要
This work was undertaken to investigate the efficacy of gefitinib, an EGFR tyrosine kinase inhibitor, in tumor cell lines of the CNS by studying cell proliferation and phosphorylation of the tyrosine kinase domain ofThe study included neuroblastoma (SHSY5Y) and glioblastoma (A172) cell lines. The MTT cell proliferation assay was performed in order to quantify the cytotoxic effect of gefitinib in A172 and SH-SY5Y cells, whilst ELISA assay was used to assess the effect on the phosphorylation of tyrosine residue 1068 of EGFR.As the concentration of gefitinib increased, MTT conversion into formazan was observed to progressively decrease, confirming the cytotoxic activity of gefitinib. In the ELISA assay for both cell lines investigated, as the dose of gefitinib increased, a gradual decrease in EGFR tyrosine phosphorylation was detected.The findings of the current study could form the basis of research regarding the use of novel inhibitors in the treatment of solid tumors in pediatric patients and a shift to targeted therapy with higher efficacy and fewer side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI